Vaxart VXRT shares are trading higher on Tuesday after the company announced the first subject has been dosed in its Phase 1 study of VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate. B. Riley also reiterated a Buy rating on the stock.
Vaxart is a biopharmaceutical company focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally.
Vaxart shares traded up 7.66% to $7.59 on Tuesday. The stock has a 52-week high of $17.49 and a 52-week low of 27 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Newswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in